Pub Date : 2023-12-07DOI: 10.1007/s40336-023-00605-0
Thaiza Goncalves Rocha, Carla Barros de Oliveira, Roberto José Pessoa de Magalhães Filho, Angelo Maiolino, Marcela Baraúna Magno, Davi da Silva Barbirato, Eduardo Murad Villoria, Lucianne Cople Maia, Sandra Regina Torres, Maria Augusta Visconti
Objective
Review, qualify and synthesize the evidence that compared computed tomography (CT) images with magnetic resonance imaging (MRI) in detecting multiple myeloma (MM) lesions in the skull, through a systematic review.
Methods
Searches were performed in six databases and the grey literature, up to August 2023, without restriction by date or publication language. Observational studies comparing CT images and MRI of the skull of patients previously diagnosed with MM were included. Data were extracted by two reviewers in a standardized and independent manner. The methodological quality assessment was performed using the QUADAS-2 tool and the evidence certainty assessment using the GRADE tool.
Results
Of the 911 identified references, 11 were included, and they all used either positron emission computed tomography (PET/CT) and/or low-dose computed tomography (LDCT) to compare to MRI. In 6 of 7 studies, MRI demonstrated a greater capacity to detect MM lesions than PET/CT images. When compared with LDCT images, MRI showed lower detection capacity in 4 studies. Six of the 11 included articles had a low risk of bias. However, as observational data evidence, the assessed certainty of the evidence was considered very low.
Conclusions
PET/CT and MRI images presented limitations in detecting MM lesions in the skull compared to LDCT images. The evidence suggested that the greatest detection capability could be achieved by employing whole-body MRI complemented by LDCT images of the skull. Future studies are needed to confirm this result.
{"title":"Comparison between computed tomography and magnetic resonance imaging in detecting multiple myeloma lesions in the skull: A systematic review","authors":"Thaiza Goncalves Rocha, Carla Barros de Oliveira, Roberto José Pessoa de Magalhães Filho, Angelo Maiolino, Marcela Baraúna Magno, Davi da Silva Barbirato, Eduardo Murad Villoria, Lucianne Cople Maia, Sandra Regina Torres, Maria Augusta Visconti","doi":"10.1007/s40336-023-00605-0","DOIUrl":"https://doi.org/10.1007/s40336-023-00605-0","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>Review, qualify and synthesize the evidence that compared computed tomography (CT) images with magnetic resonance imaging (MRI) in detecting multiple myeloma (MM) lesions in the skull, through a systematic review.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Searches were performed in six databases and the grey literature, up to August 2023, without restriction by date or publication language. Observational studies comparing CT images and MRI of the skull of patients previously diagnosed with MM were included. Data were extracted by two reviewers in a standardized and independent manner. The methodological quality assessment was performed using the QUADAS-2 tool and the evidence certainty assessment using the GRADE tool.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Of the 911 identified references, 11 were included, and they all used either positron emission computed tomography (PET/CT) and/or low-dose computed tomography (LDCT) to compare to MRI. In 6 of 7 studies, MRI demonstrated a greater capacity to detect MM lesions than PET/CT images. When compared with LDCT images, MRI showed lower detection capacity in 4 studies. Six of the 11 included articles had a low risk of bias. However, as observational data evidence, the assessed certainty of the evidence was considered very low.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>PET/CT and MRI images presented limitations in detecting MM lesions in the skull compared to LDCT images. The evidence suggested that the greatest detection capability could be achieved by employing whole-body MRI complemented by LDCT images of the skull. Future studies are needed to confirm this result.</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138547776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-20DOI: 10.1007/s40336-023-00603-2
Zhan Xu, Yimeng Shi, Hongyan Yin, Jing Lv
Purpose
This study explored the feasibility of 68gallium (Ga)-labeled novel fibroblast activation protein (FAP)-targeted ligand for tumor imaging through small-animal PET/CT (positron emission computed tomography/computed tomography).
Methods
The FAP-ligand (FL) was created by adding the chelating group dodecane tetraacetic acid (DOTA) and labeling with 68Ga. The MC38 cell line was used to establish a C57BL/6 mice colon cancer model. The radioactivity distribution of labeled 68Ga-DOTA-FL across various organs of the mouse model was examined ex-vivo. In addition, 68Ga-DOTA-FL tumor-targeted imaging in vivo was performed using small-animal PET/CT. Finally, western blotting and immunofluorescence imaging of MC38 cells and xenotransplant tumor tissues were conducted.
Results
The radiolabeling rate and radiochemical purity of 68Ga-DOTA-FL were above 95%. Both western blotting and immunofluorescence imaging revealed FAP expression in the tumor tissues, but not in the MC38 cells. Small-animal PET/CT imaging indicated that the tumor imaging was clearest at 30 min after 68Ga-DOTA-FL treatment. Examination of the radioactivity distribution in vitro revealed that at 30 min after the 68Ga-DOTA-FL treatment, the target/non-target ratio for tumor and muscle tissue was 4.0 ± 0.3 (n = 3).
Conclusions
68Ga-DOTA-FL can be used for the specific tumor imaging in mouse models, which might provide a novel alternative for FAP-targeted tumor imaging.
{"title":"Preliminary study of a novel FAP-targeted ligand 68Ga-DOTA-FL in colon cancer imaging using small-animal PET/CT","authors":"Zhan Xu, Yimeng Shi, Hongyan Yin, Jing Lv","doi":"10.1007/s40336-023-00603-2","DOIUrl":"https://doi.org/10.1007/s40336-023-00603-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This study explored the feasibility of <sup>68</sup>gallium (Ga)-labeled novel fibroblast activation protein (FAP)-targeted ligand for tumor imaging through small-animal PET/CT (positron emission computed tomography/computed tomography).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The FAP-ligand (FL) was created by adding the chelating group dodecane tetraacetic acid (DOTA) and labeling with <sup>68</sup>Ga. The MC38 cell line was used to establish a C57BL/6 mice colon cancer model. The radioactivity distribution of labeled <sup>68</sup>Ga-DOTA-FL across various organs of the mouse model was examined ex-vivo. In addition, <sup>68</sup>Ga-DOTA-FL tumor-targeted imaging in vivo was performed using small-animal PET/CT. Finally, western blotting and immunofluorescence imaging of MC38 cells and xenotransplant tumor tissues were conducted.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The radiolabeling rate and radiochemical purity of <sup>68</sup>Ga-DOTA-FL were above 95%. Both western blotting and immunofluorescence imaging revealed FAP expression in the tumor tissues, but not in the MC38 cells. Small-animal PET/CT imaging indicated that the tumor imaging was clearest at 30 min after <sup>68</sup>Ga-DOTA-FL treatment. Examination of the radioactivity distribution in vitro revealed that at 30 min after the <sup>68</sup>Ga-DOTA-FL treatment, the target/non-target ratio for tumor and muscle tissue was 4.0 ± 0.3 (<i>n</i> = 3).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p><sup>68</sup>Ga-DOTA-FL can be used for the specific tumor imaging in mouse models, which might provide a novel alternative for FAP-targeted tumor imaging.</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138539079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-13DOI: 10.1007/s40336-023-00604-1
Luca Filippi, Cristina Ferrari, Susanna Nuvoli, Francesco Bianconi, Davide Donner, Andrea Marongiu, Paolo Mammucci, Viola Vultaggio, Franca Chierichetti, Giuseppe Rubini, Angela Spanu, Orazio Schillaci, Barbara Palumbo, Laura Evangelista
{"title":"Pet-radiomics in lymphoma and multiple myeloma: update of current literature","authors":"Luca Filippi, Cristina Ferrari, Susanna Nuvoli, Francesco Bianconi, Davide Donner, Andrea Marongiu, Paolo Mammucci, Viola Vultaggio, Franca Chierichetti, Giuseppe Rubini, Angela Spanu, Orazio Schillaci, Barbara Palumbo, Laura Evangelista","doi":"10.1007/s40336-023-00604-1","DOIUrl":"https://doi.org/10.1007/s40336-023-00604-1","url":null,"abstract":"","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136347051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-05DOI: 10.1007/s40336-023-00600-5
Arosh S. Perera Molligoda Arachchige, Niccolò Stomeo
{"title":"Rethinking Patient Communication in Radiology and Nuclear Medicine: Striking a Balance for Optimal Care","authors":"Arosh S. Perera Molligoda Arachchige, Niccolò Stomeo","doi":"10.1007/s40336-023-00600-5","DOIUrl":"https://doi.org/10.1007/s40336-023-00600-5","url":null,"abstract":"","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134975094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-05DOI: 10.1007/s40336-023-00601-4
Ismet Sarikaya
{"title":"PET receptor imaging in breast cancer","authors":"Ismet Sarikaya","doi":"10.1007/s40336-023-00601-4","DOIUrl":"https://doi.org/10.1007/s40336-023-00601-4","url":null,"abstract":"","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135436217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-26DOI: 10.1007/s40336-023-00595-z
Kathleen A. Young, Tristan Raoult, Lucia Leccisotti, Bernhard L. Gerber, Panithaya Chareonthaitawee, Olivier Gheysens
{"title":"Multimodality imaging for diagnosis, risk stratification, and treatment monitoring of cardiac sarcoidosis","authors":"Kathleen A. Young, Tristan Raoult, Lucia Leccisotti, Bernhard L. Gerber, Panithaya Chareonthaitawee, Olivier Gheysens","doi":"10.1007/s40336-023-00595-z","DOIUrl":"https://doi.org/10.1007/s40336-023-00595-z","url":null,"abstract":"","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134960620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-20DOI: 10.1007/s40336-023-00589-x
Amit Nautiyal, Sofia Michopoulou, Matt Guy
{"title":"Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review","authors":"Amit Nautiyal, Sofia Michopoulou, Matt Guy","doi":"10.1007/s40336-023-00589-x","DOIUrl":"https://doi.org/10.1007/s40336-023-00589-x","url":null,"abstract":"","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136308253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-19DOI: 10.1007/s40336-023-00599-9
Alice Lorenzoni, Sebastiano Nazzani, Giovanni Argiroffi, Mario Catanzaro, Gianluca Aliberti, Nicola Nicolai, Marco Maccauro
{"title":"Sentinel node biopsy in male genitourinary cancers: state of the art and future developments","authors":"Alice Lorenzoni, Sebastiano Nazzani, Giovanni Argiroffi, Mario Catanzaro, Gianluca Aliberti, Nicola Nicolai, Marco Maccauro","doi":"10.1007/s40336-023-00599-9","DOIUrl":"https://doi.org/10.1007/s40336-023-00599-9","url":null,"abstract":"","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135063606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-16DOI: 10.1007/s40336-023-00593-1
Lizhao Huang, Lu Li, Xiaoqi Huang, Ling Chen, Li Zhu, Tao Li, Shaojun Chen
{"title":"A systematic review of radiomics for predicting treatment response and survival in locally advanced cervical cancer: positive results or optimistic illusions?","authors":"Lizhao Huang, Lu Li, Xiaoqi Huang, Ling Chen, Li Zhu, Tao Li, Shaojun Chen","doi":"10.1007/s40336-023-00593-1","DOIUrl":"https://doi.org/10.1007/s40336-023-00593-1","url":null,"abstract":"","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135306446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号